Literature DB >> 6732837

Effect of cationic amphiphilic drugs on the hydrolysis of acidic and neutral phospholipids by liver lysosomal phospholipase A.

A Pappu, K Y Hostetler.   

Abstract

Rat liver lysosomal phospholipase A hydrolyzes both acidic and neutral phospholipids. Numerous cationic amphiphilic drugs including imipramine, propranolol, 4,4'-bis(diethylaminoethoxy)-alpha, beta- diethyldiphenylethane and chloropromazine inhibit phospholipase A. Cationic amphiphilic drugs bind readily to acidic phospholipids but much less readily to neutral phospholipids. Formation of drug-lipid complexes is thought to be an important mechanism involved in the inhibition of lysosomal phospholipases. Therefore, we studied the effects of four cationic amphiphilic inhibitors on lysosomal phospholipase A using one acidic and two neutral phospholipid substrates. The concentration of the drugs required to produce 50% inhibition was much higher when phosphatidylinositol was used as substrate. The degradation of phosphatidylethanolamine and phosphatidylcholine was more readily inhibited by these agents than that of phosphatidylinositol. In drug-induced lipidosis, the predominance of acidic phospholipids may be due to redirection of phospholipid metabolism towards the formation of acidic phospholipids with a resultant increased delivery of these lipids to lysosomes. Based on our results, it does not appear to be due to decreased enzymatic hydrolysis of drug-acidic phospholipid complexes, at least when pure phospholipid substrates are used. Lysosomal storage of both acidic and neutral phospholipids appears to be caused by inhibition of lysosomal phospholipase action in view of the probable high intralysosomal levels of these agents.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6732837     DOI: 10.1016/0006-2952(84)90286-7

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  7 in total

1.  Increased levels of urinary phenylacetylglycine associated with mitochondrial toxicity in a model of drug-induced phospholipidosis.

Authors:  Lucette Doessegger; Georg Schmitt; Barbara Lenz; Holger Fischer; Götz Schlotterbeck; Elke-Astrid Atzpodien; Hans Senn; Laura Suter; Miklos Csato; Stefan Evers; Thomas Singer
Journal:  Ther Adv Drug Saf       Date:  2013-06

Review 2.  Drug targeting of sphingolipid metabolism: sphingomyelinases and ceramidases.

Authors:  Daniel Canals; David M Perry; Russell W Jenkins; Yusuf A Hannun
Journal:  Br J Pharmacol       Date:  2011-06       Impact factor: 8.739

3.  A phospholipase inhibitor modifies the pulmonary damage associated with peritonitis in rabbits.

Authors:  D Tighe; R Moss; J Parker-Williams; J Hynd; E D Bennett
Journal:  Intensive Care Med       Date:  1987       Impact factor: 17.440

4.  Predicting phospholipidosis using machine learning.

Authors:  Robert Lowe; Robert C Glen; John B O Mitchell
Journal:  Mol Pharm       Date:  2010-09-10       Impact factor: 4.939

5.  Effect of a series of 1-alkyl ether lipids on inhibition of phospholipase A2 activity and PAF responses.

Authors:  C Kohler; M Carroll; E Tarrant; L Torley; A Wissner
Journal:  Inflammation       Date:  1993-06       Impact factor: 4.092

6.  Predicting the mechanism of phospholipidosis.

Authors:  Robert Lowe; Hamse Y Mussa; Florian Nigsch; Robert C Glen; John Bo Mitchell
Journal:  J Cheminform       Date:  2012-01-26       Impact factor: 5.514

7.  Alterations in endo-lysosomal function induce similar hepatic lipid profiles in rodent models of drug-induced phospholipidosis and Sandhoff disease.

Authors:  Emmanuelle Lecommandeur; David Baker; Timothy M Cox; Andrew W Nicholls; Julian L Griffin
Journal:  J Lipid Res       Date:  2017-04-04       Impact factor: 5.922

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.